Clinical AI works in Indonesian hospitals but flounders outside them: promising diagnostic and telemedicine results are undermined by patchy broadband, fragmented regulation and limited workforce readiness, risking foreign vendor dependence and lost economic gains unless coordinated policy and investment follow.

Main Finding

Indonesia has demonstrated strong clinical efficacy of AI in healthcare (notably diagnostics, telemedicine, and chronic disease management) but faces significant implementation gaps in infrastructure, regulation, and workforce capacity. Without coordinated policy reform, targeted investment, and equity-focused deployment, Indonesia risks underutilizing AI’s potential to advance universal health coverage and the Golden Indonesia 2045 agenda.

Key Points

• Clinical performance: AI shows high efficacy in select applications (example: diabetic retinopathy screening reported accuracy ≈ 89.3%).
• National maturity: Indonesia’s AI healthcare maturity score ≈ 52/100, trailing regional peers (Singapore ≈ 92, Malaysia ≈ 78).
• Workforce readiness: Approximately 58.7% of relevant health workforce lacks AI competence or literacy needed for safe, scalable adoption.
• Governance gaps: Fragmented regulation, limited transparency/explainability requirements, and weak procurement/governance frameworks hinder uptake and accountability.
• Infrastructure and equity: Rural digital divides and uneven infrastructure constrain reach and risk exacerbating health inequities unless explicitly addressed.
• Risk of dependency: Current strategy risks technological dependency on foreign vendors if domestic capability, data governance, and procurement are not strengthened.
• Strategic priorities identified: coordinated policy reform, infrastructure investment, workforce training, and equity-focused implementation.

Data & Methods

• Review type: Narrative synthesis and thematic analysis.
• Timeframe and sources: Literature from 2020–2025 (PubMed, Google Scholar, Garuda, SINTA), plus 42 supplementary documents including national policy papers, SATUSEHAT governance reports, and Delphi consensus studies.
• Themes analyzed: clinical applications, regulatory frameworks, infrastructure, workforce readiness, and equity.
• Benchmarking: Comparative assessment against regional maturity catalogues and international standards (EU AI Act, Singapore, Australia).

Implications for AI Economics

• Investment priorities and returns
  • Infrastructure (broadband, cloud, edge compute, interoperable health data systems) is a precondition for scalable returns; underinvestment will dampen health and economic gains.
  • Prioritizing primary-care and diagnostics AI can yield high-value health returns (reduced morbidity, earlier treatment) and improve system efficiency.
• Market structure and domestic industry
  • Clear, harmonized regulation and procurement strategies can stimulate domestic AI suppliers, reduce dependency on foreign vendors, and capture more local economic value.
  • Without capacity-building, market concentration around multinational vendors may increase, capturing rents outside the domestic economy.
• Labor markets and human capital
  • Workforce upskilling (clinical AI literacy, data governance, technical roles) is necessary to realize productivity gains; training investments will have medium-term returns via improved care efficiency and reduced error rates.
  • Failure to retrain could produce structural mismatch and slow adoption, reducing realized economic benefits.
• Equity and demand-side economics
  • Digital divides suppress demand in rural and underserved populations, lowering aggregate health gains and economic productivity improvements; targeted subsidies and infrastructure rollout can unlock latent demand and more equitable benefits.
• Regulatory and adoption economics
  • Strong transparency, explainability, and safety requirements increase initial compliance costs but raise trust and long-run adoption, thereby improving uptake and avoiding costly recalls or litigation.
  • Alignment with international standards (e.g., EU AI Act principles) can facilitate cross-border partnerships and exports but requires calibration to domestic capacity.
• Policy levers with high economic leverage
  • Coordinated national AI-health strategy linking procurement, reimbursement, and certification to domestic capacity-building.
  • Public investment in digital health infrastructure with conditionalities for interoperability and local skills development.
  • Subsidized training programs and certification for clinicians and technologists to accelerate absorptive capacity.
  • Equity-focused rollout (targeted rural deployments, affordability measures) to maximize social returns and progress toward universal health coverage.

Overall, realizing AI’s economic benefits in Indonesian healthcare requires simultaneous investments in infrastructure, regulation, and human capital, coupled with governance that ensures equitable access and supports domestic industry development.